ANI Pharmaceuticals, Inc. (ANIP) one of today’s top gainers but are analysts standing by stock?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is trending higher in the market today as the company shares are trading 4.17% or 3.02 points up from last closing price of $72.48, reaching $75.5 at last check. Any clue why there is so much of action in the ANIP stock? The share price has risen in 5 of the last 5 days and is up 1.73% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -124,286 shares, and in total 148614 shares valued at $11.22 million were seen changing hands compared with 272900 shares valued at $19.78 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in ANIP stock for the next couple of days.

ANI Pharmaceuticals, Inc. (ANIP) shares have notched a 3-month gain of about 1.73%, but has still advanced 61% year to date. By comparison, the stock added 30.85% over the past 12 months, while it jumped 0.6% over the 1 month. The company’s market cap is around $874.83M, with its short interest ratio standing at 8.53%.

In the current trading session for ANIP, the stock witnessed two major price actions, it rose to a high of $76.17 and was down as much as $71.57 at one point. The high recorded is very low when compared to their 52-week high which is $36.92. The 52-week high is now at -13.17 distance from current price. Their recent low of $86.96 represents a 104.52% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ANIP is $85.5, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of ANI Pharmaceuticals, Inc. earned $1.44 per share in the trailing 12 months and has a P/E ratio of 52.43. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is higher than the ones recorded by the industry which is 30.46 and higher compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ANIP also has P/S multiple of 4.24. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.34x.

ANIP‘s last price was up 14.52% as compared to the average trading price of 50 days recorded at $65.93 while enlarging the period to 200 trading days, the average closing price was $74.9. At present, there are 12.07 million in the total number of common shares owned by the public and among those 9.32 million shares have been available to trade. The percentage of shares being held by the company management was 3.3% while institutions stake was 92.6%. The company has generated positive returns on equity over the last 12 months (8.7%). It managed to keep its gross profit margin at 69.3% over the past 12 months.

When assessing the full upside of the ANIP stock, there is another set of technicals that should be looked into and considered. Its 13.18% gain from moving average of $66.71 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.21 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of ANI Pharmaceuticals, Inc. — 4 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $84.25 on shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), which corresponds to 11.22% upside potential than its current market price of $75.5 and implies potential despite the recent advance in the price. However, their current target price has fallen from $87 a month ago and is down handily from the consensus target of $87 a quarter ago.

In the last five years, the EPS of the company has been roughly 27.4%. Though the percentage looks encouraging, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 2.7%. The revenue of the company has risen at an average annualized rate of about 46.3 over the last five years. The company recently recorded an increase of 15%, but this figure is rather attractive.

Let’s briefly check the hedge fund interest towards ANIP stock. Hancock Whitney Corp added position in the company after it grew 1.4% or 11,288 shares of its common stock. The hedge fund now owns 11,446 shares worth $864,173, SEC documents show. Nomura Holdings Inc. shored up assets in the stock as 279976.9 shares have been purchased, increasing its stake by 34.1% to 375,449 shares which are currently valued at $28,346,400. In addition, Phocas Financial Corp. recently reported that it now owns 127,391 shares making a total of $9,618,021 based on the recent price. This refelects a change of -9.6% in their ownership.